Exacerbation of Raynaud's phenomenon induced by Fremanezumab in meridional Brazil: A case report
Fernando KowacsBackground
As calcitonin gene-related peptide (CGRP)-pathway-blocking therapies become more widely used, infrequent adverse events related to impaired compensatory peripheral vasodilation or to microvasculature regulation, such as Raynaud's phenomenon and alopecia, not observed in pivotal trials, have been described.
Case
We report a case of Raynaud's phenomenon exacerbation – with no serious consequences and that did not require treatment interruption – during fremanezumab treatment, in a patient suffering from chronic migraine and medication overuse headache living in a temperate climate zone in southern Brazil.
Conclusion
This case report shows that Raynaud's phenomenon does not seem to be an absolute contraindication to CGRP-pathway-blocking therapies but reinforces the need to assess prior peripheral vascular symptoms in individuals who are candidates for its use, even in temperate regions.